As drug makers struggle to get medicines out the door, executives involved in the process say that it’s taking more time than ever to get mid-stage and late-stage clinical trials up and running.
The average amount of time from identifying useful study sites to launching a Phase 2 or Phase 3 trial now takes 31.4 weeks, or nearly eight months, which is one month longer than a decade ago, according to a survey conducted by the Tufts Center for the Study of Drug Development.
“One month may not sound like a lot, but it’s a big deal, especially when you’re trying to get multiple studies started,” said Mary Jo Lamberti, a senior research fellow at Tufts. “Time is money and it adds up, and impacts the process further down the line.”
About the Author Reprints
Vírus irtás